ArticleHuman mutation2025
M1 Macrophage is a Novel Potential Trigger for Endothelial Senescence: Role of Exosomal miR-155 Targeting SOCS1 Signal.
Article in Human mutation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Cellular senescence and regulated cell death in cancer: mechanisms, cross-regulatory networks and therapeutic implications.Journal of hematology & oncology · 2026Review
- Role of miR-155 and miR-103 in Oxidative Stress in Cardiovascular Disease: A Narrative Review.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Opposing functions of miR-155-5p and Socs1 drive vascular inflammation in diabetes-accelerated atherosclerosis.Cardiovascular diabetology · 2026Article
- The EV-mitochondrial outsourcing network as a therapeutic target for age-related testosterone deficiency: from network collapse to clinical intervention.Frontiers in endocrinology · 2026Review
- Global research trends on exosomes in atherosclerosis: a bibliometric and scientometric analysis (2004-2025).Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related proinflammatory microenvironment induced by infiltration of M1 macrophages promotes endothelial senescence-mediated vascular diseases. Macrophages exert their immunomodulatory effects by releasing exosomes. However, the underlying mechanisms governing endothelial cell senescence induced by exosomes derived from M1 macrophages (M1-Exo) remain elusive. In this study, we delved into the intricate interplay between endothelial function and M1 macrophage abundance in the aortas and explored the pivotal role of M1-Exo in endothelial cell senescence and its associated molecular pathways. Our results unveiled a compelling correlation between the infiltration of M1 macrophages in the aortas of aged mice and impaired endothelium-dependent dilatation. Coculturing endothelial cells with M1-Exo engendered the acquisition of a senescent phenotype, marked by increased senescence-associated beta-galactosidase level and a distinct senescence-associated secretory profile. Endothelial cells cocultured with M1-Exo exhibited pronounced signs of cell cycle arrest, accompanied by mitochondrial oxidative damage and dysfunction. Bioinformatics analysis and subsequent validation identified high expression of miR-155 in M1-Exo. The transfer of miR-155 contributed to the prosenescence effect of M1-Exo by targeting SOCS1, subsequently activating JAK2/STAT3 signaling. The administration of M1-Exo into young mice instigated endothelial dysfunction and increased ROS production. Notably, the reduction of miR-155 in M1-Exo partially mitigated such deleterious effects. Our findings demonstrate that exosomal miR-155, originating from M1 macrophages, elicits endothelial cell senescence. The present study brings a groundbreaking insight into the communication between M1 macrophages and endothelial cells as a mediator of vascular aging, providing a promising target for interventions in age-related vascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.